PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Pulmonary Adenocarcinoma: Approaches to Treatment10.1016/b978-0-323-55433-6.00008-02019133-142Approach to Anaplastic Lymphoma Kinase (ALK) Gene Rearranged Non–Small Cell Lung Cancer (NSCLC)Shirish Gadgeelhttps://api.elsevier.com/content/article/PII:B9780323554336000080?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780323554336000080?httpAccept=text/plain
Cancers10.3390/cancers91001382017910138From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)Michael Werner, Qian Zhang, Mariusz Wasikhttps://www.mdpi.com/2072-6694/9/10/138/pdf
Cancers10.3390/cancers91101482017912148Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human CancersAbdulraheem Alshareefhttp://www.mdpi.com/2072-6694/9/11/148/pdf
Journal of Korean Medical Science10.3346/jkms.2018.33.e12320183315Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase InhibitorsJongmin Sim, Hyunjin Kim, Jiyeon Hyeon, Yoon-La Choi, Joungho Hanhttps://jkms.org/pdf/10.3346/jkms.2018.33.e123, https://jkms.org/DOIx.php?id=10.3346/jkms.2018.33.e123, https://jkms.org/DOIx.php?id=10.3346/jkms.2018.33.e123
Reactions Weekly10.1007/s40278-017-35603-y201716681131-131Crizotinibhttp://link.springer.com/article/10.1007/s40278-017-35603-y/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-017-35603-y.pdf, http://link.springer.com/content/pdf/10.1007/s40278-017-35603-y.pdf
Cancers10.3390/cancers91001412017912141An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-PositiveSuzanne Turnerhttp://www.mdpi.com/2072-6694/9/10/141/pdf
Reactions Weekly10.1007/s40278-018-43852-z20181695124-24Alectinibhttp://link.springer.com/content/pdf/10.1007/s40278-018-43852-z.pdf, http://link.springer.com/article/10.1007/s40278-018-43852-z/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-018-43852-z.pdf
Science-Business eXchange10.1038/scibx.2008.4312008118431-431Anaplastic lymphoma kinase (ALK)http://link.springer.com/content/pdf/10.1038/scibx.2008.431.pdf, http://link.springer.com/article/10.1038/scibx.2008.431/fulltext.html, http://link.springer.com/content/pdf/10.1038/scibx.2008.431.pdf
Cancer Treatment Communications10.1016/j.ctrc.2015.03.001201546-9Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case reportKhalid Al-Baimani, Harman S. Sekhon, Paul Wheatley-Pricehttps://api.elsevier.com/content/article/PII:S2213089615000080?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2213089615000080?httpAccept=text/plain
Pharmacological Research10.1016/j.phrs.2017.01.0072017117343-356Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancersRobert Roskoskihttps://api.elsevier.com/content/article/PII:S1043661817300166?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S1043661817300166?httpAccept=text/xml